生物标志物指导的玻璃体视网膜疾病管理:影像、药物治疗与手术决策整合
本文为叙述性综述,综合OCT与OCTA衍生影像生物标志物证据,探讨其在玻璃体视网膜疾病中预测疾病行为、治疗反应和手术指征的作用。综述指出DRIL、HRF、视网膜内/下积液模式及血管灌注变化等标志物有助于分层表型、区分血管生成与炎症模式,并指导抗VEGF、糖皮质激素及新型长效药物的个体化使用和手术时机选择。
要点
- OCT/OCTA标志物如DRIL、HRF、积液模式和灌注变化可分层疾病表型并指导管理。
- 生物标志物方法可区分血管生成与炎症模式,支持个体化治疗策略。
- 影像标志物在识别手术候选者和确定干预时机中起核心作用。
核心结论
- 生物标志物指导的方法为个体化玻璃体视网膜诊疗提供了临床可操作的框架。
- 多模态影像与药物及手术决策的整合是迈向精准医学的关键步骤,有望改善结局并减少治疗负担。
研究设计与样本
- 叙述性综述,整合已发表证据与临床见解,聚焦OCT和OCTA衍生生物标志物。
主要发现
- 关键影像生物标志物包括视网膜内层结构紊乱(DRIL)、高反射灶(HRF)、视网膜内和视网膜下积液模式及血管灌注变化。
- 这些标志物在分层疾病表型和指导管理方面具有显著价值。
- 生物标志物方法可区分血管生成与炎症模式,支持个体化治疗策略。
- 个体化策略包括优化抗血管内皮生长因子治疗、糖皮质激素治疗及新型长效药物的使用。
- 影像生物标志物在识别手术候选者和确定干预时机中起核心作用,尤其在牵拉性黄斑病变和难治性疾病中。
临床怎么用
- 利用OCT/OCTA标志物分层疾病表型,区分血管生成与炎症模式以指导个体化用药。
- 依据影像生物标志物优化抗VEGF、糖皮质激素及新型长效药物的使用。
- 借助影像标志物识别手术候选者并确定干预时机,尤其针对牵拉性黄斑病变和难治性疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To synthesize current evidence on imaging biomarkers in vitreoretinal diseases and to review the potential for a biomarker-guided framework integrating imaging, pharmacotherapy, and surgical decision-making in contemporary clinical practice. METHODS: This narrative review integrates published evidence and clinical insights on optical coherence tomography (OCT) and OCT angiography (OCTA)-derived biomarkers, focusing on their role in predicting disease behavior, therapeutic response, and surgical indications. RESULTS: Key imaging biomarkers-including disorganization of the retinal inner layers (DRIL), hyperreflective foci (HRF), intraretinal and subretinal fluid patterns, and vascular perfusion changes-demonstrate significant value in stratifying disease phenotype and guiding management. Biomarker-based approaches enable differentiation between angiogenic and inflammatory patterns, supporting individualized therapeutic strategies. These include optimized use of anti-vascular endothelial growth factor therapy, corticosteroid-based treatments, and newer long-acting agents. In addition, imaging biomarkers play a central role in identifying surgical candidates and determining timing of intervention, particularly in tractional maculopathies and refractory disease. CONCLUSION: A biomarker-guided approach provides a clinically actionable framework for personalized vitreoretinal care. The integration of multimodal imaging with pharmacologic and surgical decision-making represents a critical step toward precision medicine, with the potential to improve outcomes and reduce treatment burden.
引用
- Iglicki M, Zur D, Melamud JI, et al. Biomarker-Guided Management in Vitreoretinal Diseases: Integrating Imaging, Pharmacotherapy, and Surgical Decision-Making-A Narrative Review. Retina. 2026. PMID: 42627258. doi:10.1097/IAE.0000000000004984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。